Home Interview Nigeria must take ownership of its pharmaceutical value chain – Mounemeh

Nigeria must take ownership of its pharmaceutical value chain – Mounemeh

0
32
Nigeria must take ownership of its pharmaceutical value chain – Mounemeh
Pharm. Frank Mounemeh

Pharm. Frank Mounemeh is the executive secretary of the Pharmaceutical Manufacturing Group of the Manufacturers Association of Nigeria (PMG-MAN). In this interview with Patrick Iwelunmor, he speaks on the forthcoming Nigeria Pharma Manufacturers Expo, medicine security, Nigeria’s emerging role as a regional manufacturing hub and other pertinent issues affecting the pharmaceutical industry.

The Nigeria Pharma Manufacturers Expo promises to be a major event this year. What should stakeholders expect from the expo, and what makes this edition particularly important?

At the core of the PMG-MAN Manufacturers Expo is the drive for medicine security and national development. We want to draw the attention of policymakers and other stakeholders to the importance of local pharmaceutical manufacturing in achieving medicine security. This year’s Expo is particularly important because the industry is transitioning towards greater self-sufficiency in the production of medicines and pharmaceutical products.

We expect close to 200 companies and between 3,000 and 4,000 participants and visitors. Exhibitors will come from Asia, India, China, Europe and neighbouring African countries, with international exhibitors primarily bringing machinery, active pharmaceutical ingredients, packaging materials, clean rooms, HVAC systems and laboratory equipment that support local manufacturing.

 

What opportunities does the expo offer young Nigerians and pharmacists who may want to enter pharmaceutical manufacturing?

Many young people are not sufficiently focused on pharmaceutical manufacturing, while some traders see it as an investment beyond their reach. We want the expo to demonstrate that Nigeria is an important destination for pharmaceutical investment.

Established founders and CEOs will share their experiences and journeys with the next generation of entrepreneurs. There will also be technical sessions for pharmacists and other professionals covering supply chain management, quality assurance, quality control, regulatory affairs, market access, production management and engineering.

As a pharmacist, I believe pharmacists should play a much greater role in pharmaceutical manufacturing. The expo will help professionals understand the opportunities available to them and acquire skills that are transferable across the industry. There will also be discussions on emerging areas such as contract research organisations and bioequivalence studies.

 

You have repeatedly emphasised medicine security. What exactly does medicine security mean and why is local manufacturing so important to achieving it?

Medicine security means Nigeria taking ownership of how the medicines and life science products it consumes are produced. That means being in the driver’s seat in research and development, supply chain management, last-mile delivery, regulation and, most importantly, end-to-end production, from active pharmaceutical ingredients to finished products.

Until we contribute sufficiently to the entire value chain, access to safe, quality and affordable medicines will remain difficult. Universal health coverage will also remain rhetoric because access to medicines is critical to achieving it. If Nigerians are still paying between 70 and 76 per cent of their healthcare expenses out of pocket, particularly for medicines, health equity becomes difficult, especially when more than 130 million Nigerians are living in multidimensional poverty.

 

Nigeria is increasingly being described as an important pharmaceutical manufacturing hub in Africa. How do you assess Nigeria’s position in the regional pharmaceutical manufacturing landscape?

Nigeria is becoming a strong player in regional manufacturing. There is significant investment in the pharmaceutical sector; the industry is recording annual growth, and Nigeria contributes a significant proportion of pharmaceutical products consumed across West and Central Africa.

Excluding North Africa, Nigeria is the next major hub for regional manufacturing. That has guided our expo theme, which focuses on regional manufacturing and advancing Africa’s pharmaceutical and life sciences sovereignty through localisation. You cannot achieve regional manufacturing without strengthening local manufacturing. We want to play local but become stronger at the regional and African levels and help close the medicine access gap.

 

How does the African Continental Free Trade Area fit into this vision of regional pharmaceutical manufacturing?

The African Continental Free Trade Area is an important part of this conversation. The opportunity is enormous. We are looking at how Nigeria can strengthen its manufacturing capacity and use that capacity to serve other African markets.

It is not simply about producing for Nigeria. We are looking at building a stronger African pharmaceutical manufacturing ecosystem while contributing to skills development, capacity building, investment and regional economic development.

 

Some multinational pharmaceutical companies have exited Nigeria in recent years. Has their departure been entirely negative, or has it created opportunities for local manufacturers?

Some multinationals left with products they previously manufactured here, but the local industry turned that window into an opportunity. Local companies began focusing on gaps created in the market and manufacturing essential products that were previously supplied by those companies.

Today, we have close to 10 beta-lactam facilities manufacturing products in that category. Nigerian manufacturers are also producing molecules that, 10 years ago, we would not have considered manufacturing locally. We are even looking at opportunities such as biosimilar products.

 

NAFDAC’s 5+5 policy has been widely discussed within the pharmaceutical industry. What impact would you say the policy has had on local manufacturing?

The NAFDAC 5+5 policy is very significant, and I commend the director-general of NAFDAC for faithfully implementing it. Where there is evidence of the capability and capacity to manufacture a product locally, companies with market authorisation must either demonstrate plans to manufacture locally or provide evidence of contract manufacturing in Nigeria.

The policy has transformed the system. Companies that have held market authorisations for years are now establishing manufacturing facilities, while existing local manufacturers are positioning themselves for contract manufacturing.

When people ask whether government should prioritise finance or policy, I say policy is fundamental. With the right policy, companies are compelled to align with the direction of government, seek financing and get the job done.

 

Apart from the 5+5 policy, the Federal Government has introduced a presidential executive order to support local pharmaceutical manufacturing. What impact is this having on manufacturers?

The presidential executive order has been supportive, particularly in encouraging members to repurpose facilities and contribute more to local manufacturing. However, implementation has presented challenges.

The executive order provides a 7.5 per cent incentive, which we appreciate, but implementation has not always been aligned with the original intention. It took almost another month after the order was declared for the technical working group to develop the implementation framework. The intention was to support machinery and pharmaceutical ingredients, but the machinery component did not succeed as initially intended. Implementation was largely limited to APIs and certain packaging materials, with several policy adjustments along the way.

 

What specific problems have manufacturers encountered in the implementation of these policies?

One challenge has been inconsistencies in the platforms used for trade and customs processes. Manufacturers experienced difficulties with the B’Odogwu platform and had to engage government over charges they believed they should not have been paying.

The platform was later replaced by the National Single Window, but members are still reporting inconsistencies and additional charges. These problems increase production costs.

Manufacturers also face congestion at the ports, where delays in clearing pharmaceutical inputs can disrupt production cycles. Containers may be diverted to other ports or tracking systems may not accurately reflect their physical location. All these delays create additional costs, which ultimately affect the price paid by patients.

 

Energy costs have also been identified as a major burden on manufacturers. How serious is the situation?

It is a very serious issue. Manufacturers can spend as much as 40 per cent of their production costs on energy, compared with countries such as India and China, where energy costs are significantly lower. In China, the figure is almost less than five per cent.

These costs eventually become part of the price of the product leaving the factory. Ultimately, the patient bears the cost. So, when we discuss medicine prices, we must understand the entire production ecosystem and the numerous costs manufacturers face.

 

Finally, if you were to identify the single biggest challenge facing pharmaceutical manufacturing in Nigeria today, what would it be, and what should government do differently?

Policy. When you ask what government should prioritise, the conversation usually comes down to policy and finance. If I have to choose, I will say policy. The NAFDAC 5+5 policy is a clear example of what the right policy can achieve.

The biggest challenge is policy consistency and faithful implementation. A policy can be well thought out and beautifully written in black and white, but if its execution is flawed, the desired outcome will not be achieved. I always say that we are taught at Harvard that policy design is 10 per cent, while execution is 90 per cent. Our major problem is in that 90 per cent: execution.

Everything is connected. Logistics challenges and energy costs significantly affect manufacturers, while access to finance remains another major issue.

We welcome the presidential executive order, but we are asking for its extension for another two years to give the policies sufficient time to stabilise and produce their intended impact. What we need is consistency. Policy can be excellent on paper, but its success depends on faithful and effective implementation. That is how we can strengthen local pharmaceutical manufacturing, improve medicine security and ensure that Nigerians have better access to safe, quality and affordable medicines.

LEAVE A REPLY

Please enter your comment!
Please enter your name here